ArticleJournal of virology2003
Development and application of a reverse genetics system for Japanese encephalitis virus.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 131 citations in OpenAlex.
- A versatile fluorescent reporter for Usutu virus drug screening and infection tracking.PNAS nexus · 2026Article
- Article
- Reverse Genetics of Orthoflaviviruses: Strategies for Constructing Functional or Infectious cDNA.Journal of medical virology · 2026Review
- Article
- Research Progress and Applications of the Rotavirus Reverse Genetics System.Animals : an open access journal from MDPI · 2026Review
- A Bovine Cell Line Resistant to Japanese Encephalitis Virus Entry but Permissive to Post-Entry Replication.Viruses · 2026Article
- Article
- Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SAInternational journal of molecular sciences · 2024Article
- Generation of rescued Japanese encephalitis virus genotype 1 from infectious full-size clone using reverse genetics.Heliyon · 2024Article
- Insights into the Pathogenesis and Development of Recombinant Japanese Encephalitis Virus Genotype 3 as a Vaccine.Vaccines · 2024Article
- Applying Reverse Genetics to Study Measles Virus Interactions with the Host.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Article
- An in vitro workflow to create and modify infectious clones using replication cycle reaction.Virology · 2023Article
- Reporter Flaviviruses as Tools to Demonstrate Homologous and Heterologous Superinfection Exclusion.Viruses · 2022Article
- Article
- Reinventing positive-strand RNA virus reverse genetics.Advances in virus research · 2022Article
- Applications of Deep Mutational Scanning in Virology.Viruses · 2021Review
- Reverse genetics systems for contemporary isolates of respiratory syncytial virus enable rapid evaluation of antibody escape mutants.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Recovery and Genetic Characterization of a West Nile Virus Isolate from China.Virologica Sinica · 2021Article
- Identifying optimal capsid duplication length for the stability of reporter flaviviruses.Emerging microbes & infections · 2020Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Japanese encephalitis virus (JEV) is a common agent of viral encephalitis that causes high mortality and morbidity among children. Molecular genetic studies of JEV are hampered by the lack of a genetically stable full-length infectious JEV cDNA clone. We describe here the development of such a clone. A JEV isolate was fully sequenced, and then its full-length cDNA was cloned into a bacterial artificial chromosome. This was then further engineered so that transcription of the cDNA in vitro would generate synthetic RNAs with authentic 5' and 3' ends. The synthetic RNAs thus produced were highly infectious in susceptible cells (>10(6) PFU/ micro g), and these cells rapidly generated a high titer of synthetic viruses (>5 x 10(6) PFU/ml). The recovered viruses were indistinguishable from the parental virus in terms of plaque morphology, growth kinetics, RNA accumulation, protein expression, and cytopathogenicity. Significantly, the structural and functional integrity of the cDNA was maintained even after 180 generations of growth in Escherichia coli. A single point mutation acting as a genetic marker was introduced into the cDNA and was found in the genome of the recovered virus, indicating that the cDNA can be manipulated. Furthermore, we showed that JEV is an attractive vector for the expression of heterologous genes in a wide variety of cell types. This novel reverse genetics system for JEV will greatly facilitate research into JEV biology. It will also be useful as a heterologous gene expression vector and will aid the development of a vaccine against JEV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.